Last reviewed 2026-06-10 · How we verify

Pain due to Osteoblastic Bone Metastasis — Treatment Landscape & Competitive Intelligence

Pain due to Osteoblastic Bone Metastasis (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Marketed treatment landscape

Approved drugs treating Pain due to Osteoblastic Bone Metastasis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

1. Lantheus Medical · 1 drug in Pain due to Osteoblastic Bone Metastasis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pain due to Osteoblastic Bone Metastasis:

• Pain due to Osteoblastic Bone Metastasis treatment updates — RSS
• Pain due to Osteoblastic Bone Metastasis treatment updates — Atom
• Pain due to Osteoblastic Bone Metastasis treatment updates — JSON

Cite this brief

Drug Landscape (2026). Pain due to Osteoblastic Bone Metastasis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pain-due-to-osteoblastic-bone-metastasis. Accessed 2026-06-10.

Related

• Pain due to Osteoblastic Bone Metastasis full disease profile — treatment pathway, diagnostics, guidelines
• Browse all CI briefs
• Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing